Editorials
- CSF analysis in suspected MSDo bands aid?Rogier Q. Hintzen, Gavin Giovannoni
- Responsiveness and predictive values in PPMSAn uncertain messageGary R. Cutter, Fred D. Lublin
- Starting earlyMRI evidence of gray matter atrophy in children with multiple sclerosisBrenda L. Banwell, John G. Sled
- Biomarkers for interferon response in MSAre we there yet?Richard A. Rudick, Richard M. Ransohoff
- The diagnosis of MSWhite spots and red flagsJohn N. Ratchford, Peter A. Calabresi
- Myelin, mitochondria, and autoimmunityWhat's the connection?Valerio Carelli, Marzio Bellan
Articles
- Do oligoclonal bands add information to MRI in first attacks of multiple sclerosis?M. Tintoré, A. Rovira, J. Río, C. Tur, R. Pelayo, C. Nos, N. Téllez, H. Perkal, M. Comabella, J. Sastre-Garriga, X. Montalban
- Responsiveness and predictive value of EDSS and MSFC in primary progressive MSJ. J. Kragt, A. J. Thompson, X. Montalban, M. Tintoré, J. Río, C. H. Polman, B.M.J. Uitdehaag
- Regression of new gadolinium enhancing lesion activity in relapsing-remitting multiple sclerosisYinshan Zhao, Anthony Traboulsee, A. John Petkau, David Li
- Modeling Uhthoff's phenomenon in MS patients with internuclear ophthalmoparesisS. L. Davis, T. C. Frohman, C. G. Crandall, M. J. Brown, D. A. Mills, P. D. Kramer, O. Stüve, E. M. Frohman
- Evidence of thalamic gray matter loss in pediatric multiple sclerosisS. Mesaros, M. A. Rocca, M. Absinta, A. Ghezzi, N. Milani, L. Moiola, P. Veggiotti, G. Comi, M. Filippi
- Integrating risk factorsHLA-DRB1*1501 and Epstein–Barr virus in multiple sclerosisP. L. De Jager, K. C. Simon, K. L. Munger, J. D. Rioux, D. A. Hafler, A. Ascherio
- Predictive markers for response to interferon therapy in patients with multiple sclerosisS. Malucchi, F. Gilli, M. Caldano, F. Marnetto, P. Valentino, L. Granieri, A. Sala, M. Capobianco, A. Bertolotto
- Sporadic adult-onset leukoencephalopathy with neuroaxonal spheroids mimicking cerebral MSB. M. Keegan, C. Giannini, J. E. Parisi, C. F. Lucchinetti, B. F. Boeve, K. A. Josephs
Clinical/Scientific Notes
- POSTWITHDRAWAL REBOUND INCREASE IN T2 LESIONAL ACTIVITY IN NATALIZUMAB-TREATED MS PATIENTSM. M. Vellinga, J. A. Castelijns, F. Barkhof, B.M.J. Uitdehaag, C. H. Polman
- MULTIPLE SCLEROSIS–LIKE DISORDER IN OPA1-RELATED AUTOSOMAL DOMINANT OPTIC ATROPHYC. Verny, D. Loiseau, C. Scherer, P. Lejeune, A. Chevrollier, N. Gueguen, V. Guillet, F. Dubas, P. Reynier, P. Amati-Bonneau, D. Bonneau
- INTERFERON β-ASSOCIATED RETINOPATHY IN PATIENTS TREATED FOR MULTIPLE SCLEROSISDavid V. Folden, Michael S. Lee, Edwin H. Ryan
- TNFRSF1A R92Q MUTATION IN ASSOCIATION WITH A MULTIPLE SCLEROSIS–LIKE DEMYELINATING SYNDROMEL. A. Hoffmann, P. Lohse, F. B. König, W. Feneberg, R. Hohlfeld, T. Kümpfel
Conference Report
- Ethics of placebo-controlled clinical trials in multiple sclerosisA reassessmentC. H. Polman, S. C. Reingold, F. Barkhof, P. A. Calabresi, M. Clanet, J. A. Cohen, G. R. Cutter, M. S. Freedman, L. Kappos, F. D. Lublin, H. F. McFarland, L. M. Metz, A. E. Miller, X. Montalban, P. W. O'Connor, H. Panitch, J. R. Richert, J. Petkau, S. R. Schwid, M. P. Sormani, A. J. Thompson, B. G. Weinshenker, J. S. Wolinsky
Issues in neurologic Practice
- Access to and utilization of neurologists by people with multiple sclerosisS. L. Minden, D. C. Hoaglin, L. Hadden, D. Frankel, T. Robbins, J. Perloff